Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells <i>In Vitro, In Vivo</i> , and <i>Ex Vivo</i>
Cited by 51
Related Papers
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|384
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
|Cancer Research|2010|348